You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

EVENTS

ISTH, Kedrion supports symposium on the importance of inhibitor eradication

The central theme of the round table will be the optimization of the treatment of patients with Hemophilia A

read more 

EVENTS

Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020

The company reaffirms its commitment to the patient community during the COVID-19 epidemic

read more 

CORPORATE

Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel

The two companies are now working to expand the Clinical Development Program to the US

read more 

  1. CORPORATE - 16-02-2018

    Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

    The prize is awarded to the companies that made the best use of the capital markets

    read more 

  2. EVENTS - 14-02-2018

    Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

    Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

    read more 

  3. CORPORATE - 10-01-2018

    Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

    Goal is to improve access to replacement therapies for coagulation disorders in Europe

    read more 

  4. EVENTS - 09-11-2017

    Kedrion Biopharma joins IPOPI in supporting patients with APP PID Genius

    This new APP, presented at the IPIC Congress in Dubai, will be the personal assistant to people living with PIDs

    read more 

Pages

For more information please contact: pressoffice@kedrion.com